$ESMC
ESCALON MEDICAL CORP Stock $esmc

$esmc Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000086266820000013 Filed on November 16, 2020

Income Statement

Concept	2020 Q3	2019 Q3	2018 Q3
Revenue	$2.414M	$2.288M	$2.258M
YoY Change	5.5%	1.31%	-14.12%
Cost Of Revenue	$1.504M	$1.177M	$1.203M
YoY Change	27.81%	-2.2%	-18.0%
Gross Profit	$909.9K	$1.111M	$1.055M
YoY Change	-18.12%	5.31%	-9.21%
Gross Profit Margin	37.7%	48.57%	46.73%
Selling, General & Admin	$892.2K	$999.4K	$1.002M
YoY Change	-10.73%	-0.28%	0.58%
% of Gross Profit	98.05%	89.93%	94.98%
Research & Development	$209.3K	$245.6K	$96.41K
YoY Change	-14.78%	154.79%	-50.07%
% of Gross Profit	23.0%	22.1%	9.14%
Depreciation & Amortization	$11.30K	$11.91K	$13.19K
YoY Change	-5.06%	-9.71%	11.23%
% of Gross Profit	1.24%	1.07%	1.25%
Operating Expenses	$1.101M	$1.245M	$1.099M
YoY Change	-11.53%	13.33%	-7.64%
Operating Profit	-$191.6K	-$133.7K	-$43.40K
YoY Change	43.24%	208.21%	59.12%
Interest Expense	$5.518K	$3.984K	$6.851K
YoY Change	38.5%	-41.85%	-79.52%
% of Operating Profit
Other Income/Expense, Net	-$4.979K	$755.1K	-$4.341K
YoY Change	-100.66%	-17495.07%	-86.94%
Pretax Income	-$196.6K	$621.4K	-$50.00K
YoY Change	-131.63%	-1342.74%	-16.67%
Income Tax
% Of Pretax Income
Net Earnings	-$196.6K	$621.4K	-$47.74K
YoY Change	-131.63%	-1401.69%	-21.12%
Net Earnings / Revenue	-8.14%	27.16%	-2.11%
Basic Earnings Per Share	-$0.03	$0.08	-$0.01
Diluted Earnings Per Share	-$0.03	$0.05	-$0.01
COMMON SHARES
Basic Shares Outstanding	7.415M shares	7.415M shares	7.415M shares
Diluted Shares Outstanding	7.415M shares	12.19M shares	7.415M shares

Balance Sheet

Concept	2020 Q3	2019 Q3	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.366M	$415.8K	$910.0K
YoY Change	228.5%	-54.31%	111.63%
Cash & Equivalents	$1.366M	$415.8K	$415.8K
Short-Term Investments
Other Short-Term Assets	$178.8K	$227.7K	$257.0K
YoY Change	-21.45%	-11.43%	11.53%
Inventory	$1.585M	$1.785M	$1.969M
Prepaid Expenses
Receivables	$1.046M	$1.355M	$1.422M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.431M	$4.153M	$4.610M
YoY Change	6.7%	-9.92%	9.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$90.82K	$60.90K	$74.50K
YoY Change	49.13%	-18.25%	47.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$62.79K	$62.79K
YoY Change	0.0%
Total Long-Term Assets	$1.312M	$1.921M	$835.9K
YoY Change	-31.69%	129.82%	0.52%
TOTAL ASSETS
Total Short-Term Assets	$4.431M	$4.153M	$4.610M
Total Long-Term Assets	$1.312M	$1.921M	$835.9K
Total Assets	$5.743M	$6.074M	$5.446M
YoY Change	-5.44%	11.53%	8.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$919.6K	$691.4K	$679.0K
YoY Change	33.01%	1.82%	-33.22%
Accrued Expenses	$814.1K	$619.4K	$744.2K
YoY Change	31.42%	-16.76%	-29.34%
Deferred Revenue
YoY Change
Short-Term Debt	$201.6K	$201.6K	$201.6K
YoY Change	0.0%	0.0%	-76.83%
Long-Term Debt Due	$3.490K	$3.490K	$0.00
YoY Change	0.0%
Total Short-Term Liabilities	$3.191M	$2.432M	$2.321M
YoY Change	31.22%	4.76%	-25.99%
LONG-TERM LIABILITIES
Long-Term Debt	$354.9K	$13.98K	$20.00K
YoY Change	2438.77%	-30.1%
Other Long-Term Liabilities	$881.8K	$844.5K	$740.0K
YoY Change	4.43%	14.12%	-5.13%
Total Long-Term Liabilities	$1.237M	$858.5K	$760.3K
YoY Change	44.07%	12.91%	-2.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.191M	$2.432M	$2.321M
Total Long-Term Liabilities	$1.237M	$858.5K	$760.3K
Total Liabilities	$4.428M	$3.290M	$3.082M
YoY Change	34.57%	6.77%	-21.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$69.04M	-$67.57M	-$67.99M
YoY Change	2.17%	-0.62%	-0.87%
Common Stock	$7.415K	$7.415K	$7.415K
YoY Change	0.0%	0.0%	-1.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.315M	$2.784M	$2.365M
YoY Change
Total Liabilities & Shareholders Equity	$5.743M	$6.074M	$5.446M
YoY Change	-5.44%	11.53%	8.05%

Cashflow Statement

Concept	2020 Q3	2019 Q3	2018 Q3
OPERATING ACTIVITIES
Net Income	-$196.6K	$621.4K	-$47.74K
YoY Change	-131.63%	-1401.69%	-21.12%
Depreciation, Depletion And Amortization	$11.30K	$11.91K	$13.19K
YoY Change	-5.06%	-9.71%	11.23%
Cash From Operating Activities	$541.1K	$7.166K	$11.83K
YoY Change	7450.64%	-39.44%	-106.96%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	-$10.00K
YoY Change		-100.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$9.390K	-$6.506K
YoY Change		44.33%	-55.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$889.00	-$822.00	$36.07K
YoY Change	8.15%	-102.28%	-51.91%
NET CHANGE
Cash From Operating Activities	$541.1K	$7.166K	$11.83K
Cash From Investing Activities		-$9.390K	-$6.506K
Cash From Financing Activities	-$889.00	-$822.00	$36.07K
Net Change In Cash	$540.2K	$6.344K	$41.40K
YoY Change	8414.97%	-84.67%	-136.24%
FREE CASH FLOW
Cash From Operating Activities	$541.1K	$7.166K	$11.83K
Capital Expenditures		$0.00	-$10.00K
Free Cash Flow		$7.166K	$21.83K
YoY Change		-67.18%	-113.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q3	dei	Amendment Flag AmendmentFlag	false
CY2020Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2020Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2020Q3	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
CY2020Q3	dei	Document Type DocumentType	10-Q
CY2020Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000862668
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7415329	shares
CY2020Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q3	dei	Entity Registrant Name EntityRegistrantName	ESCALON MEDICAL CORP.
CY2020Q3	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q3	esmc	Increasedecreaseinliabilitiesofdiscontinuedoperations Increasedecreaseinliabilitiesofdiscontinuedoperations	-3439	USD
CY2020Q3	esmc	Increasedecreaseinliabilitiesofdiscontinuedoperations Increasedecreaseinliabilitiesofdiscontinuedoperations	3664	USD
CY2020Q3	esmc	Interestportioninthefutureleasepayments Interestportioninthefutureleasepayments	130501	USD
CY2020Q3	esmc	Maximum Maturity Of Highly Liquid Investments Period MaximumMaturityOfHighlyLiquidInvestmentsPeriod	P90D
CY2020Q3	esmc	Netpresentvalueofnewleasefuturepayments Netpresentvalueofnewleasefuturepayments	1110261	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	760621	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	919567	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1312935	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1045537	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	681047	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	814062	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69702043	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69702043	USD
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	123000	USD
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	105000	USD
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	213000	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5361527	shares
CY2020Q2	us-gaap	Assets Assets	5722577	USD
CY2020Q3	us-gaap	Assets Assets	5743165	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	4333397	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	4430747	USD
CY2018Q2	us-gaap	Cash Cash	662878	USD
CY2018Q3	us-gaap	Cash Cash	669222	USD
CY2020Q2	us-gaap	Cash Cash	1081239	USD
CY2020Q3	us-gaap	Cash Cash	1621429	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	409743	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	415818	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	825958	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1365954	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	662878	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	669222	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1081239	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1621429	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6344	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	540190	USD
CY2020Q3	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	4300000
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	35000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	35000000	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7415329	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7415329	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7415329	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7415329	shares
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	7415	USD
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	7415	USD
CY2020Q3	us-gaap	Common Stock Voting Rights CommonStockVotingRights	0.7781
CY2020	us-gaap	Concentration Risk Supplier ConcentrationRiskSupplier	two
CY2020Q3	us-gaap	Concentration Risk Supplier ConcentrationRiskSupplier	three
CY2020Q3	us-gaap	Convertible Preferred Dividends Net Of Tax ConvertiblePreferredDividendsNetOfTax	0	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1176670	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1503869	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	2421735	USD
CY2020Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	2.15	shares
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	2605368	USD
CY2019Q2	us-gaap	Deferred Revenue DeferredRevenue	427000	USD
CY2019Q3	us-gaap	Deferred Revenue DeferredRevenue	427000	USD
CY2020Q2	us-gaap	Deferred Revenue DeferredRevenue	516000	USD
CY2020Q3	us-gaap	Deferred Revenue DeferredRevenue	467000	USD
CY2019Q3	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	235000	USD
CY2020Q3	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	181000	USD
CY2020Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	516053	USD
CY2020Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	467500	USD
CY2019Q3	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	235000	USD
CY2020Q3	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	230000	USD
CY2019Q2	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.045
CY2020Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	62789	USD
CY2020Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	62792	USD
CY2019Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11906	USD
CY2020Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11303	USD
CY2019Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	13006	USD
CY2020Q2	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.06
CY2020Q3	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.0678
CY2018Q1	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.03
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2020Q3	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.3670
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	141282	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	267788	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	262579	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	321029	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	122050	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	117137	USD
CY2020Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2019Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	24851	USD
CY2020Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	158946	USD
CY2019Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-141000	USD
CY2020Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-267398	USD
CY2019Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	33295	USD
CY2020Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	133015	USD
CY2019Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-333	USD
CY2020Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-48553	USD
CY2019Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	21820	USD
CY2020Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-200069	USD
CY2019Q3	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	0	USD
CY2020Q3	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	35864	USD
CY2019Q3	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-10873	USD
CY2020Q3	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2019Q3	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4585	USD
CY2020Q3	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	24630	USD
CY2019Q3	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	-25473	USD
CY2020Q3	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	0	USD
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	4773120	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2019Q3	us-gaap	Interest Expense InterestExpense	3984	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	5518	USD
CY2019Q3	us-gaap	Interest Paid Net InterestPaidNet	5827	USD
CY2020Q3	us-gaap	Interest Paid Net InterestPaidNet	2854	USD
CY2020Q2	us-gaap	Interest Payable Current InterestPayableCurrent	112389	USD
CY2020Q3	us-gaap	Interest Payable Current InterestPayableCurrent	112389	USD
CY2020Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	849000	USD
CY2020Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	791000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	1785030	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	1785000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	1585000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	1584961	USD
CY2020Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	613000	USD
CY2020Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	655000	USD
CY2020Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	323000	USD
CY2020Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	139000	USD
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1083	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	539	USD
CY2019Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	104449	USD
CY2020Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	93861	USD
CY2020Q3	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P12M
CY2020Q2	us-gaap	Liabilities Liabilities	4210618	USD
CY2020Q3	us-gaap	Liabilities Liabilities	4427759	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5722577	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5743165	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2865007	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3190997	USD
CY2020Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1345611	USD
CY2020Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1236762	USD
CY2020Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	89990	USD
CY2020Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	93654	USD
CY2020Q2	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	8872	USD
CY2020Q3	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	44736	USD
CY2020Q3	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	201575	USD
CY2020Q3	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.0624
CY2019Q3	us-gaap	Line Of Credit Facility Periodic Payment Interest LineOfCreditFacilityPeriodicPaymentInterest	3639	USD
CY2020Q3	us-gaap	Line Of Credit Facility Periodic Payment Interest LineOfCreditFacilityPeriodicPaymentInterest	2576	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-822	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-889	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7166	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	541079	USD
CY2020Q3	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	73754	USD
CY2019Q3	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	82910	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	621373	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-196553	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	608367	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-209523	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	621373	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-209523	USD
CY2019Q3	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	608367	USD
CY2020Q3	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-209523	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	755120	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4979	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-133747	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-191574	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1208000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	278634	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	273153	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	896533	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	837108	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1107127	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1041665	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1137878	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y11M12D
CY2020Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1240762	USD
CY2020Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	2728	USD
CY2020Q3	us-gaap	Operating Leases Future Minimum Payments Receivable Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear	245356	USD
CY2020Q2	us-gaap	Other Assets Current OtherAssetsCurrent	154193	USD
CY2020Q3	us-gaap	Other Assets Current OtherAssetsCurrent	178820	USD
CY2020	us-gaap	Other Income OtherIncome	758000	USD
CY2020Q3	us-gaap	Other Long Term Debt OtherLongTermDebt	45000	USD
CY2020Q2	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	11503	USD
CY2020Q3	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	10524	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	758021	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2020Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	3401	USD
CY2020Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	3491	USD
CY2019Q3	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	82195	USD
CY2020Q3	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	74310	USD
CY2019Q2	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent	791985	USD
CY2020Q3	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	8491	USD
CY2020	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	122709	USD
CY2020Q3	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	135679	USD
CY2019Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	13006	USD
CY2020Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12970	USD
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2000000	shares
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	645000	USD
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	645000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	97214	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90824	USD
CY2018Q1	us-gaap	Related Party Transaction Due From To Related Party RelatedPartyTransactionDueFromToRelatedParty	645000	USD
CY2019Q3	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	822	USD
CY2020Q3	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	889	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	245638	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	209322	USD
CY2018Q2	us-gaap	Restricted Cash RestrictedCash	253135	USD
CY2018Q3	us-gaap	Restricted Cash RestrictedCash	253404	USD
CY2020Q2	us-gaap	Restricted Cash RestrictedCash	255281	USD
CY2020Q3	us-gaap	Restricted Cash RestrictedCash	255475	USD
CY2020Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	255281	USD
CY2020Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	255475	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68842499	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-69039052	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2287988	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2413794	USD
CY2020Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	0	USD
CY2020Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	942	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	999427	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	892177	USD
CY2020Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	201575	USD
CY2020Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	201575	USD
CY2019Q3	us-gaap	Short Term Lease Payments ShortTermLeasePayments	99569	USD
CY2020Q3	us-gaap	Short Term Lease Payments ShortTermLeasePayments	89800	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	2162239	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	2783612	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1511959	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	1315406	USD
CY2020Q3	us-gaap	Unsecured Debt UnsecuredDebt	500000	USD
CY2020Q2	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	221297	USD
CY2020Q3	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	304664	USD
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12188449	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7415329	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7415329.0	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7415329	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7415329	shares
CY2020Q3	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">          Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), Escalon Holdings, Inc. (“EHI”), Escalon IP Holdings, Inc., and Sonomed IP Holdings, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, and reflect all adjustments (consisting of only normal and recurring adjustments) which are, in the opinion of management, necessary to present fairly the unaudited condensed consolidated financial information required herein. Certain information and note disclosures normally included in financial statement prepared in accordance with accounting principles generally accepted in the United Statements of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. While management believes that the disclosures are adequate to make the information presented not misleading, it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed with the Security and Exchange Commission for the fiscal year ended June 30, 2020. The results of operations for the three months ended September 30, 2020 are not necessarily indicative of the results to be expected for the full year. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) a pandemic. This pandemic has had a significant impact on the global and domestics economy, and is likely to impact the operations of the Company. The Company has been assessing the impact of the COVID-19 pandemic on the business, including the impact on the financial condition and results of operations, financial resources, changes in accounting judgment as well as the impact on the supply and demand, etc. The Company is considered an essential business and has been able to maintain operations during the lockdown. The Company applied for and received $500,000 in April 2020 under the Payroll Protection Program (PPP loan) which will help reverse the negative impact in terms of the liquidity. The maturity date is two years from the date of the note. The interest rate is 1.00% per year. The Company remains in strong communications with the customers and there is no evidence showing that COVID-19 will greatly affect collection of accounts receivable as of date of this filing. However, the Company does not know the extent and duration of the impact of COVID-19 on its business due to the uncertainty about the spread of the virus.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”</font></div></div>
CY2020Q3	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally affected in the US Generally Accepted Accounting Principles ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000862668-20-000013-index-headers.html	Edgar Link	pending
0000862668-20-000013-index.html	Edgar Link	pending
0000862668-20-000013.txt	Edgar Link	pending
0000862668-20-000013-xbrl.zip	Edgar Link	pending
esmc-20200930.xml	Edgar Link	completed
esmc-20200930.xsd	Edgar Link	pending
esmc-20200930_cal.xml	Edgar Link	unprocessable
esmc-20200930_def.xml	Edgar Link	unprocessable
esmc-20200930_lab.xml	Edgar Link	unprocessable
esmc-20200930_pre.xml	Edgar Link	unprocessable
esmc_20200930-10qex311.htm	Edgar Link	pending
esmc_20200930-10qex312.htm	Edgar Link	pending
esmc_20200930-10qex321.htm	Edgar Link	pending
esmc_20200930-10qex322.htm	Edgar Link	pending
esmc_2020930-10q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESMC
ESCALON MEDICAL CORP Stock $esmc

2020 Q3 Form 10-Q Financial Statement

#000086266820000013 Filed on November 16, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESMC ESCALON MEDICAL CORP Stock $esmc

2020 Q3 Form 10-Q Financial Statement

#000086266820000013 Filed on November 16, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESMC
ESCALON MEDICAL CORP Stock $esmc